Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries : Announces Reintroduction of Generic Depo-Provera® in the United States

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:01pm CEST

By a News Reporter-Staff News Editor at Clinical Trials Week -- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL, in the United States. Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy (see also Pharmaceutical Companies).

"This reintroduction brings an additional product to a market that was previously lacking in options," said Dr. Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D. "In addition to its importance to patients who will benefit from access to this medicine, this reintroduction holds significant importance to Teva and our generics R&D priorities."

Teva has been committed to strengthening its generic injectable business globally, by making continued investment in newer, higher-value generic injectable products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in seven generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Medroxyprogesterone acetate injectable suspension, USP 150 mg/mL had annual sales of approximately $211 million in the United States, according to IMS data as of July 2017. About Medroxyprogesterone Acetate Injectable Suspension, USP Medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate injectable suspension long-term. Important Safety InformationWomen who use medroxyprogesterone acetate injectable suspension may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible. Medroxyprogesterone acetate injectable suspension should not be used as a long-term birth control method (i.e., longer than 2 years) unless other birth control methods are considered inadequate. The use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: known or suspected pregnancy or as a diagnostic test for pregnancy; active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease; known or suspected malignancy of breast; known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients; significant liver disease; or undiagnosed vaginal bleeding.

Studies have shown an increased risk of breast cancer in women using medroxyprogesterone acetate injectable suspension. Serious thrombotic events; anaphylaxis and anaphylactoid reaction; injection site reactions; convulsions; weight gain; and decreased glucose tolerance have been reported with the use of medroxyprogesterone acetate injectable suspension.

In clinical trials the most common adverse reactions (incidence > 5%) were: menstrual irregularities (bleeding or spotting), abdominal pain/discomfort, dizziness, headache, nervousness, and decreased libido. Medroxyprogesterone acetate injectable suspension does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Keywords for this news article include: Antineoplastics, Pharmaceutical Companies, Teva Pharmaceutical Industries Ltd, Oncology, Progestins, Sex Hormones, Bone Research, Breast Cancer, Contraceptives, Drugs and Therapies, Risk and Prevention, Breast Ductal Carcinoma, Medroxyprogesterone Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
10/23 TEVA PHARMACEUTICAL INDUSTRIES : Glancy Prongay & Murray Reminds Investors of th..
10/23 TEVA PHARMACEUTICAL INDUSTRIES : to Highlight New Data in Multiple Sclerosis at ..
10/21 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : 3-DAY DEADLINE: Khang & Khang LLP Announc..
10/20 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE MONDAY: Levi & Korsinsky, LLP Re..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE MONDAY: Lundin Law PC Announces ..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : to Report Third Quarter 2017 Financial Results ..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : The Law Offices of Vincent Wong Reminds I..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : Announces Submission of Biologics License Appli..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : to Highlight New Data in Multiple Sclerosis at ..
10/18 TEVA REMINDER DEADLINE ALERT : The Law Offices of Howard G. Smith Reminds Invest..
More news
News from SeekingAlpha
10/23 YOUR DAILY PHARMA SCOOP : Adamis Upside Potential, J&J's SIMPONI Label Expansion..
10/23 ALLERGAN : Is Linzess 'Restasis 2.0'?
10/20 Debt-laden pharmas under pressure on Concordia's debt restructuring
10/19 J&J : Unattractive
10/18 TEVA BULLS ARE TOO EARLY : Debt Downgrade On The Way
Financials ($)
Sales 2017 22 644 M
EBIT 2017 6 282 M
Net income 2017 -
Debt 2017 34 451 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,18x
EV / Sales 2018 2,07x
Capitalization 14 900 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 28,0 $
Spread / Average Target 91%
Managers
NameTitle
Kåre Schultz President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-62.33%14 900
JOHNSON & JOHNSON23.60%385 476
NOVARTIS13.97%226 424
PFIZER12.13%216 767
ROCHE HOLDING LTD.0.77%206 094
MERCK AND COMPANY7.69%172 914